In this issue of the Journal, O'Connell et al. (1) describe the identification of a region on the long arm of chromosome 14 that is apparently involved in the progression of breast cancer toward metastasis. Measuring loss of heterozygosity, the investigators found that the majority of lymph node-negative breast tumors did not amplify a region linked to D14S62 and D14S51, while lymph node-positive breast tumors retained heterozygosity for these same markers. These data could imply the existence of a metastasis-promoting gene. Alternatively, the observed molecular changes may be a marker of metastatic propensity.
predicts metastatic propensity based on expression and/or activity of a molecule with an established role in metastasis. For example, matrix metalloproteinases would be expected to be more highly expressed in invasive and metastatic tumors than in their nonmetastatic counterparts. The second category includes markers for which there is no established mechanistic association with metastasis. This category includes known genes with potentially novel functions, novel genes, and molecular changes that correlate with metastatic ability. The markers reported by O'Connell et al. fall into this category, as do the vast majority of markers utilized today [reviewed in (8, 9) ].
Each of these categories can be further divided on the basis of on whether the marker is increased or decreased. This criterion impacts the clinical utility of the marker. Assay sensitivity for molecules that are more highly expressed in metastatic primary tumors would be greater than for those expressed at lower levels because of tumor heterogeneity. It is well recognized that the majority of cells within a tumor cannot complete the multistep process of metastasis. Indeed, less than 0.1% of cells entering the bloodstream successfully form clinically detectable lesions (7) . By inference, it follows that a similarly small percentage of cells within a primary tumor would display a marker of metastasis. Just as it is easier to see a single lighted candle in a dark room than to find the only unlit candle in a room full of lighted candles, it is easier to identify a single cell expressing a new marker against a background of nonexpressing cells than it is to find nonexpressing cells within a mass of cells that express a particular marker. This comparison does not even take into account quantitative differences in expression, which would further complicate the matter. For this reason, identification of metastasis-associated, positive regulators would be preferred by pathologists. Examples of such positive regulators include vascular endothelial growth factor, Ras, Mts1, Mta1, and Tiam1 [reviewed in (5, 10) ].
From experimental and treatment perspectives, however, identification of suppressors of metastasis offers advantages. To metastasize, cells must complete all steps of the metastatic cascade shown in Fig. 1 . If a cell fails to complete any of these steps, it is nonmetastatic. Thus, it takes only one gene to block metastasis, whereas it takes the coordinated expression of many genes to allow metastasis (6, 11) . In experimental systems, it is fairly easy to find associations with metastatic ability; however, it is difficult to prove that a particular gene is essential. For example, if one were to transfect a bona fide metastasis-promoting gene that promoted invasion into a cell that already contained a defect in another gene-say, one required for angiogenesis-that transfected cell would still be nonmetastatic. In contrast, introduction of a gene that disrupts any step in the metastatic cascade would render metastatic cells nonmetastatic. Thus, from a treatment perspective, identification of metastasissuppressing genes/products would offer the greatest advantage. To date, five such human metastasis suppressor genes have been reported: NME1 (12, 13) , KiSS1 (14, 15) , KAI1 (16, 17) , Ecadherin (18, 19) , and MKK4 (20) .
It must be emphasized that markers can be clinically useful even if their biologic function is not well defined. Indeed, we anticipate that, as a result of efforts to sequence the human genome, there will be numerous molecular markers identified in regions that have not previously been linked to gross chromosomal changes. This concept is well illustrated by the report by O'Connell et al. (1) . The immediate, critical concern for breast cancer, as well as for other cancers, is to improve the ability of the pathologist to segregate metastatic from nonmetastatic lesions unambiguously. If it is certain that the patient does not have metastases (even occult ones), treatment beyond surgical removal is not necessary. However, if metastases are present, then more aggressive treatments must begin. As with most issues, decisions are more difficult when the evidence is not clear (i.e., patients with no evidence of macroscopic metastases but for which microscopic, occult metastases are suspected). How are those patients to be treated? The underlying question relates to the level of assurance on which the suspicions are founded. In other words, how confident is the physician that the marker accurately reflects tumor stage? The goal is to avoid unnecessary, expensive treatment, which often comes with undesirable side effects.
As efforts continue toward the identification and development of molecular markers of metastasis, we should heed the experiences that tell us that the use of subjective markers of metastasis leads to ambiguity. In addition, the complexity of the metastatic process suggests that multiple markers may be needed. 
